Business Context and Reporting Period
This Form 8-K is a current report filed by Manhattan Pharmaceuticals, Inc. (noted as TG THERAPEUTICS, INC. in metadata) on January 30, 2007. The filing addresses Item 5.02 regarding the adoption of a new compensation plan for non-employee directors and the settlement of prior year fees.
Key Financial Metrics
The filing does not report revenue, profit, cash flow, margins, debt, or liquidity metrics. The only financial data provided relates to director compensation:
- Stock Price: $0.72 per share (closing price on January 30, 2007).
- Director Fees Settled: $20,000 aggregate cash fees owed for 2006 service.
- Shares Issued: 27,776 shares of common stock issued in lieu of cash fees.
- Stock Options Granted: 10-year options to purchase 50,000 shares per non-employee director at an exercise price of $0.72.
Material Changes
The primary material change is the shift in compensation structure for non-employee directors. Instead of receiving cash for 2006 services, directors accepted stock valued at the closing market price. Additionally, a new long-term equity incentive (10-year options) was adopted for the board.
Guidance, Outlook, and Risks
The filing contains no management guidance, future outlook, risk factors, or discussion of contingencies. The document is strictly limited to the disclosure of the director compensation arrangement and the issuance of equity.
Investor Verification Checklist
- Verify the total number of shares outstanding post-issuance of the 27,776 shares and the new options.
- Confirm the dilution impact of the 50,000-share options granted to each non-employee director.
- Review the full terms of the "2003 Stock Option Plan" referenced in the filing.
- Check subsequent filings for any changes in the company's name or status, as the metadata lists "TG THERAPEUTICS, INC." while the filing text identifies "Manhattan Pharmaceuticals, Inc."